Published in J Virol on October 01, 2000
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol (2005) 2.18
Nonstructural proteins NS1 and NS2 of bovine respiratory syncytial virus block activation of interferon regulatory factor 3. J Virol (2003) 2.10
Role of alpha/beta interferons in the attenuation and immunogenicity of recombinant bovine respiratory syncytial viruses lacking NS proteins. J Virol (2003) 1.98
Human respiratory syncytial virus nonstructural protein NS2 antagonizes the activation of beta interferon transcription by interacting with RIG-I. J Virol (2009) 1.70
Animal pneumoviruses: molecular genetics and pathogenesis. Clin Microbiol Rev (2004) 1.67
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58
Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol (2011) 1.57
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
Virus replication in engineered human cells that do not respond to interferons. J Virol (2003) 1.44
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis (2010) 1.36
Respiratory syncytial virus nonstructural proteins decrease levels of multiple members of the cellular interferon pathways. J Virol (2009) 1.34
Deletion of M2 gene open reading frames 1 and 2 of human metapneumovirus: effects on RNA synthesis, attenuation, and immunogenicity. J Virol (2005) 1.32
Live-attenuated virus vaccines for respiratory syncytial and parainfluenza viruses: applications of reverse genetics. J Clin Invest (2002) 1.30
Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol (2008) 1.22
Vaccinating captive chimpanzees to save wild chimpanzees. Proc Natl Acad Sci U S A (2014) 1.12
Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol (2013) 1.10
The human respiratory syncytial virus nonstructural protein 1 regulates type I and type II interferon pathways. Mol Cell Proteomics (2012) 1.08
Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol (2013) 1.01
Coupled translation of the second open reading frame of M2 mRNA is sequence dependent and differs significantly within the subfamily Pneumovirinae. J Virol (2007) 1.01
Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. MBio (2014) 1.01
Human metapneumovirus M2-2 protein inhibits innate cellular signaling by targeting MAVS. J Virol (2012) 1.00
Viral degradasome hijacks mitochondria to suppress innate immunity. Cell Res (2013) 0.99
Respiratory syncytial virus vaccine development. Clin Lab Med (2009) 0.98
Recombinant respiratory syncytial virus with the G and F genes shifted to the promoter-proximal positions. J Virol (2002) 0.98
Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol (2012) 0.97
The NS2 protein of human respiratory syncytial virus suppresses the cytotoxic T-cell response as a consequence of suppressing the type I interferon response. J Virol (2006) 0.95
The interactome of the human respiratory syncytial virus NS1 protein highlights multiple effects on host cell biology. J Virol (2012) 0.94
A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression. J Virol (2011) 0.93
Both nonstructural proteins NS1 and NS2 of pneumonia virus of mice are inhibitors of the interferon type I and type III responses in vivo. J Virol (2011) 0.93
Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol Ther (2008) 0.92
RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction. J Clin Invest (2014) 0.92
Deletion of nonstructural proteins NS1 and NS2 from pneumonia virus of mice attenuates viral replication and reduces pulmonary cytokine expression and disease. J Virol (2008) 0.89
Progress in respiratory virus vaccine development. Semin Respir Crit Care Med (2011) 0.89
Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther (2007) 0.88
Inhibitors of the interferon response enhance virus replication in vitro. PLoS One (2014) 0.84
Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates. J Virol (2011) 0.84
Overexpression of the M2-2 protein of respiratory syncytial virus inhibits viral replication. J Virol (2005) 0.83
Effects of altering the transcription termination signals of respiratory syncytial virus on viral gene expression and growth in vitro and in vivo. J Virol (2004) 0.83
Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Hum Vaccin Immunother (2013) 0.83
Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates. Virology (2009) 0.82
Paramyxovirus activation and inhibition of innate immune responses. J Mol Biol (2013) 0.81
Recombinant human parainfluenza virus type 2 with mutations in V that permit cellular interferon signaling are not attenuated in non-human primates. Virology (2010) 0.81
Replacement of the respiratory syncytial virus nonstructural proteins NS1 and NS2 by the V protein of parainfluenza virus 5. Virology (2007) 0.81
Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets (2012) 0.81
Human respiratory syncytial virus non-structural protein NS1 modifies miR-24 expression via transforming growth factor-β. J Gen Virol (2015) 0.81
Recombinant respiratory syncytial viruses lacking the C-terminal third of the attachment (G) protein are immunogenic and attenuated in vivo and in vitro. J Virol (2004) 0.79
A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity. J Gen Virol (2013) 0.78
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol (2016) 0.78
RSV-Induced H3K4 Demethylase KDM5B Leads to Regulation of Dendritic Cell-Derived Innate Cytokines and Exacerbates Pathogenesis In Vivo. PLoS Pathog (2015) 0.78
2'-5'-Oligoadenylate Synthetase-Like Protein Inhibits Respiratory Syncytial Virus Replication and Is Targeted by the Viral Nonstructural Protein 1. J Virol (2015) 0.78
Mutation of the elongin C binding domain of human respiratory syncytial virus non-structural protein 1 (NS1) results in degradation of NS1 and attenuation of the virus. Virol J (2011) 0.78
Mammalian Cell-Derived Respiratory Syncytial Virus-Like Particles Protect the Lower as well as the Upper Respiratory Tract. PLoS One (2015) 0.76
Immunological Features of Respiratory Syncytial Virus-Caused Pneumonia-Implications for Vaccine Design. Int J Mol Sci (2017) 0.75
Host cytoskeleton in respiratory syncytial virus assembly and budding. Virol J (2016) 0.75
Identification of Respiratory Syncytial Virus Nonstructural Protein 2 Residues Essential for Exploitation of the Host Ubiquitin System and Inhibition of Innate Immune Responses. J Virol (2016) 0.75
Functional motifs responsible for human metapneumovirus M2-2-mediated innate immune evasion. Virology (2016) 0.75
Respiratory syncytial virus infection: from biology to therapy: a perspective. World Allergy Organ J (2008) 0.75
Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA (1999) 8.07
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A (1995) 6.51
The V protein of simian virus 5 inhibits interferon signalling by targeting STAT1 for proteasome-mediated degradation. J Virol (1999) 4.99
Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci U S A (1996) 3.39
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol (1999) 2.80
The paramyxovirus, Sendai virus, V protein encodes a luxury function required for viral pathogenesis. EMBO J (1997) 2.71
The product of the respiratory syncytial virus M2 gene ORF1 enhances readthrough of intergenic junctions during viral transcription. J Virol (1998) 2.56
Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J Virol (1999) 2.06
The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A (1999) 1.98
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res (1994) 1.87
Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol (1998) 1.66
Low-temperature-grown RS virus in adult volunteers. JAMA (1968) 1.63
Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology (1996) 1.60
Respiratory syncytial virus and parainfluenza virus infections in the immunocompromised host. Semin Respir Infect (1995) 1.46
A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology (1995) 1.46
Respiratory syncytial virus vaccines. Clin Microbiol Rev (1998) 1.38
Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res (1999) 1.34
Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents. J Virol (2000) 1.33
Respiratory syncytial virus infection in the elderly. Eur J Clin Microbiol Infect Dis (1996) 1.01
Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine (2000) 0.98
Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates. J Virol (1999) 0.97
A single amino acid in the PB2 gene of influenza A virus is a determinant of host range. J Virol (1993) 10.22
Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A (1995) 6.51
The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins. Proc Natl Acad Sci U S A (1987) 4.93
Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters. Proc Natl Acad Sci U S A (1983) 4.69
Epidemiology of respiratory syncytial virus infection in Washington, D.C. II. Infection and disease with respect to age, immunologic status, race and sex. Am J Epidemiol (1973) 4.47
Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A (1986) 4.14
Nucleotide sequence of the G protein gene of human respiratory syncytial virus reveals an unusual type of viral membrane protein. Proc Natl Acad Sci U S A (1985) 3.93
Temperature-sensitive mutants of influenza virus. 3. Further characterization of the ts-1(E) influenza A recombinant (H3N2) virus in man. J Infect Dis (1973) 3.89
The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol (1997) 3.77
Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactiva ted virus. J Virol (1986) 3.64
Resistance to human respiratory syncytial virus (RSV) infection induced by immunization of cotton rats with a recombinant vaccinia virus expressing the RSV G glycoprotein. Proc Natl Acad Sci U S A (1986) 3.53
Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med (1972) 3.51
Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant. Proc Natl Acad Sci U S A (1997) 3.49
Hemagglutinin-specific enzyme-linked immunosorbent assay for antibodies to influenza A and B viruses. J Clin Microbiol (1981) 3.46
Nucleotide sequence of the gene encoding the fusion (F) glycoprotein of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1984) 3.42
Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol (1986) 3.33
Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst (2001) 3.28
Virulence of avian influenza A viruses for squirrel monkeys. Infect Immun (1982) 3.22
Vpx is required for dissemination and pathogenesis of SIV(SM) PBj: evidence of macrophage-dependent viral amplification. Nat Med (1998) 3.19
cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A (1983) 3.05
Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol (1995) 2.96
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol (1999) 2.80
Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology (1998) 2.76
Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. J Virol (2000) 2.75
Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol (1986) 2.67
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Titration and characterization of two rhesus-derived SIVmac challenge stocks. AIDS Res Hum Retroviruses (1994) 2.63
Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun (1982) 2.61
Rescue of synthetic analogs of genomic RNA and replicative-intermediate RNA of human parainfluenza virus type 3. J Virol (1993) 2.60
In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone. Proc Natl Acad Sci U S A (1999) 2.56
An influenza A virus containing influenza B virus 5' and 3' noncoding regions on the neuraminidase gene is attenuated in mice. Proc Natl Acad Sci U S A (1991) 2.55
Use of single-gene reassortant viruses to study the role of avian influenza A virus genes in attenuation of wild-type human influenza A virus for squirrel monkeys and adult human volunteers. J Clin Microbiol (1992) 2.50
Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill (2010) 2.49
A molecularly cloned, pathogenic, neutralization-resistant simian immunodeficiency virus, SIVsmE543-3. J Virol (1997) 2.46
Identification of a tenth mRNA of respiratory syncytial virus and assignment of polypeptides to the 10 viral genes. J Virol (1984) 2.45
Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol (1986) 2.43
Evaluation of influenza A/Hong Kong/123/77 (H1N1) ts-1A2 and cold-adapted recombinant viruses in seronegative adult volunteers. Infect Immun (1980) 2.42
Virological analysis of fatal influenza cases in the United Kingdom during the early wave of influenza in winter 2010/11. Euro Surveill (2011) 2.40
Contribution of the respiratory syncytial virus G glycoprotein and its secreted and membrane-bound forms to virus replication in vitro and in vivo. Virology (2001) 2.38
Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order. Proc Natl Acad Sci U S A (1986) 2.36
Four viral genes independently contribute to attenuation of live influenza A/Ann Arbor/6/60 (H2N2) cold-adapted reassortant virus vaccines. J Virol (1988) 2.35
Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol (1992) 2.35
New enzyme immunoassays for measurement of influenza A/Victoria/3/75 virus in nasal washes. Lancet (1980) 2.35
The B allele of the NS gene of avian influenza viruses, but not the A allele, attenuates a human influenza A virus for squirrel monkeys. Virology (1989) 2.32
Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology (2000) 2.28
Temperature-sensitive mutants of influenza virus. II. Attenuation of ts recombinants for man. J Infect Dis (1972) 2.28
Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol (1987) 2.26
Recovery of infectious human parainfluenza virus type 3 from cDNA. Virology (1997) 2.17
The envelope-associated 22K protein of human respiratory syncytial virus: nucleotide sequence of the mRNA and a related polytranscript. J Virol (1985) 2.15
Rescue of an influenza A virus wild-type PB2 gene and a mutant derivative bearing a site-specific temperature-sensitive and attenuating mutation. J Virol (1993) 2.15
Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses. Virology (1986) 2.14
Temperature-sensitive mutants of influenza A virus. XII. Safety, antigenicity, transmissibility, and efficacy of influenza A/Udorn/72-ts-1[E] recombinant viruses in human adults. J Infect Dis (1976) 2.12
Role of the M2-1 transcription antitermination protein of respiratory syncytial virus in sequential transcription. J Virol (1999) 2.11
Serum and nasal-wash immunoglobulin G and A antibody response of infants and children to respiratory syncytial virus F and G glycoproteins following primary infection. J Clin Microbiol (1986) 2.09
Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine (1995) 2.06
Evaluation of avian-human reassortant influenza A/Washington/897/80 x A/Pintail/119/79 virus in monkeys and adult volunteers. J Clin Microbiol (1986) 2.06
Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. J Virol (1999) 2.06
Respiratory syncytial virus (RSV) F, G, M2 (22K), and N proteins each induce resistance to RSV challenge, but resistance induced by M2 and N proteins is relatively short-lived. J Virol (1991) 2.05
The NS1 protein of human respiratory syncytial virus is a potent inhibitor of minigenome transcription and RNA replication. J Virol (1998) 2.02
Dose response of A/Alaska/6/77 (H3N2) cold-adapted reassortant vaccine virus in adult volunteers: role of local antibody in resistance to infection with vaccine virus. Infect Immun (1983) 2.01
Evaluation of four real-time PCR assays for detection of influenza A(H1N1)v viruses. Euro Surveill (2009) 2.01
The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A (1999) 1.98
Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus. J Virol (1996) 1.95
Identification of the respiratory syncytial virus proteins required for formation and passage of helper-dependent infectious particles. J Virol (1998) 1.95
Transcriptional map for Newcastle disease virus. J Virol (1980) 1.90
Antigenic variation in the hemagglutinin-neuraminidase protein of human parainfluenza type 3 virus. Virology (1985) 1.90
Increased expression of the N protein of respiratory syncytial virus stimulates minigenome replication but does not alter the balance between the synthesis of mRNA and antigenome. Virology (1997) 1.90
Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet (1984) 1.88
An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res (1994) 1.87
Sequence analysis of the polymerase L gene of human respiratory syncytial virus and predicted phylogeny of nonsegmented negative-strand viruses. Virology (1991) 1.87
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
Reassortant virus derived from avian and human influenza A viruses is attenuated and immunogenic in monkeys. Science (1982) 1.86
The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins. Virology (1991) 1.86
Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model. Vaccine (1996) 1.86
RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. J Virol (1996) 1.86